Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 314

1.

Longevity of total hip arthroplasty implants in patients with Gaucher disease.

Cohen D, Kogan D, Rubin A, Zimran A, Lebel E.

Hip Int. 2019 Sep 11:1120700019834919. doi: 10.1177/1120700019834919. [Epub ahead of print]

PMID:
31507221
2.

Effect of Ambroxol chaperone therapy on Glucosylsphingosine (Lyso-Gb1) levels in two Canadian patients with type 3 Gaucher disease.

Charkhand B, Scantlebury MH, Narita A, Zimran A, Al-Hertani W.

Mol Genet Metab Rep. 2019 May 17;20:100476. doi: 10.1016/j.ymgmr.2019.100476. eCollection 2019 Sep.

3.

Glucosylsphingosine (lyso-Gb1) as a Biomarker for Monitoring Treated and Untreated Children with Gaucher Disease.

Hurvitz N, Dinur T, Becker-Cohen M, Cozma C, Hovakimyan M, Oppermann S, Demuth L, Rolfs A, Abramov A, Zimran A, Revel-Vilk S.

Int J Mol Sci. 2019 Jun 21;20(12). pii: E3033. doi: 10.3390/ijms20123033.

4.

Prodromal substantia nigra sonography undermines suggested association between substrate accumulation and the risk for GBA-related Parkinson's disease.

Arkadir D, Dinur T, Becker Cohen M, Revel-Vilk S, Tiomkin M, Brüggemann N, Cozma C, Rolfs A, Zimran A.

Eur J Neurol. 2019 Jul;26(7):1013-1018. doi: 10.1111/ene.13927. Epub 2019 Mar 1.

PMID:
30714262
5.

Presenting signs and patient co-variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED-C) Delphi initiative.

Mehta A, Kuter DJ, Salek SS, Belmatoug N, Bembi B, Bright J, Vom Dahl S, Deodato F, Di Rocco M, Göker-Alpan O, Hughes DA, Lukina EA, Machaczka M, Mengel E, Nagral A, Nakamura K, Narita A, Oliveri B, Pastores G, Pérez-López J, Ramaswami U, Schwartz IV, Szer J, Weinreb NJ, Zimran A.

Intern Med J. 2019 May;49(5):578-591. doi: 10.1111/imj.14156. Erratum in: Intern Med J. 2019 Aug;49(8):1059.

PMID:
30414226
6.

Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial.

Lukina E, Watman N, Dragosky M, Lau H, Avila Arreguin E, Rosenbaum H, Zimran A, Foster MC, Gaemers SJM, Peterschmitt MJ.

Am J Hematol. 2019 Jan;94(1):29-38. doi: 10.1002/ajh.25300. Epub 2018 Oct 26.

7.

Improvement in bone marrow infiltration in patients with type I Gaucher disease treated with taliglucerase alfa.

Zimran A, Dinur T, Revel-Vilk S, Akkerman EM, van Dussen L, Hollak CEM, Maayan H, Altarescu G, Chertkoff R, Maas M.

J Inherit Metab Dis. 2018 Nov;41(6):1259-1265. doi: 10.1007/s10545-018-0195-y. Epub 2018 Jul 31.

8.

Rapid intravenous infusion of velaglucerase-alfa in adults with type 1 Gaucher disease.

Zimran A, Revel-Vilk S, Becker-Cohen M, Chicco G, Arbel N, Rolfs A, Szer J.

Am J Hematol. 2018 Sep;93(9):E246-E248. doi: 10.1002/ajh.25205. Epub 2018 Aug 9. No abstract available.

9.

How we manage Gaucher Disease in the era of choices.

Revel-Vilk S, Szer J, Mehta A, Zimran A.

Br J Haematol. 2018 Aug;182(4):467-480. doi: 10.1111/bjh.15402. Epub 2018 May 29. Review.

PMID:
29808905
10.

Bone loss and hematological malignancies in adults: a pilot study.

Ruchlemer R, Amit-Kohn M, Tvito A, Sindelovsky I, Zimran A, Raveh-Brawer D.

Support Care Cancer. 2018 Sep;26(9):3013-3020. doi: 10.1007/s00520-018-4143-z. Epub 2018 Mar 16.

PMID:
29549514
11.

Splenectomy in Gaucher Disease: A Call for Minimally Invasive Surgery.

Freund MR, Reissman P, Zimran A, Alberton J.

Surg Laparosc Endosc Percutan Tech. 2018 Apr;28(2):86-89. doi: 10.1097/SLE.0000000000000518.

PMID:
29521675
12.

Glucosylsphingosine is a reliable response biomarker in Gaucher disease.

Arkadir D, Dinur T, Revel-Vilk S, Becker Cohen M, Cozma C, Hovakimyan M, Eichler S, Rolfs A, Zimran A.

Am J Hematol. 2018 Jun;93(6):E140-E142. doi: 10.1002/ajh.25074. Epub 2018 Mar 15. No abstract available.

13.

Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease.

Zimran A, Wajnrajch M, Hernandez B, Pastores GM.

Orphanet J Rare Dis. 2018 Feb 23;13(1):36. doi: 10.1186/s13023-018-0776-8. Review.

14.

Hepatocellular carcinoma in Gaucher disease: an international case series.

Regenboog M, van Dussen L, Verheij J, Weinreb NJ, Santosa D, Vom Dahl S, Häussinger D, Müller MN, Canbay A, Rigoldi M, Piperno A, Dinur T, Zimran A, Mistry PK, Salah KY, Belmatoug N, Kuter DJ, Hollak CEM.

J Inherit Metab Dis. 2018 Sep;41(5):819-827. doi: 10.1007/s10545-018-0142-y. Epub 2018 Feb 8.

15.

Characteristics of 26 patients with type 3 Gaucher disease: A descriptive analysis from the Gaucher Outcome Survey.

Schwartz IVD, Göker-Alpan Ö, Kishnani PS, Zimran A, Renault L, Panahloo Z, Deegan P; GOS Study group.

Mol Genet Metab Rep. 2017 Dec 27;14:73-79. doi: 10.1016/j.ymgmr.2017.10.011. eCollection 2018 Mar.

16.

Demographics and patient characteristics of 1209 patients with Gaucher disease: Descriptive analysis from the Gaucher Outcome Survey (GOS).

Zimran A, Belmatoug N, Bembi B, Deegan P, Elstein D, Fernandez-Sasso D, Giraldo P, Goker-Alpan O, Lau H, Lukina E, Panahloo Z, Schwartz IVD; GOS Study group.

Am J Hematol. 2018 Feb;93(2):205-212. doi: 10.1002/ajh.24957. Epub 2017 Dec 12.

17.

Should eliglustat be first line therapy for patients with type 1 Gaucher disease? Definitions of safety and efficacy.

Zimran A, Goldblatt J, Szer J.

Blood Cells Mol Dis. 2018 Feb;68:14-16. doi: 10.1016/j.bcmd.2017.09.003. Epub 2017 Sep 14. Review. No abstract available.

PMID:
28935503
18.

Recent advances and future challenges in Gaucher disease.

Zimran A, Szer J.

Blood Cells Mol Dis. 2018 Feb;68:9-13. doi: 10.1016/j.bcmd.2017.08.016. Epub 2017 Sep 8. No abstract available.

PMID:
28918238
19.

Preface to the special issue on Gaucher disease 2017.

Zimran A, Szer J.

Blood Cells Mol Dis. 2018 Feb;68:1-2. doi: 10.1016/j.bcmd.2017.08.015. Epub 2017 Sep 8. No abstract available.

PMID:
28918237
20.

Reductions in glucosylsphingosine (lyso-Gb1) in treatment-naïve and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: Data from phase 3 clinical trials.

Elstein D, Mellgard B, Dinh Q, Lan L, Qiu Y, Cozma C, Eichler S, Böttcher T, Zimran A.

Mol Genet Metab. 2017 Sep;122(1-2):113-120. doi: 10.1016/j.ymgme.2017.08.005. Epub 2017 Aug 24.

21.

Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians.

Mehta A, Belmatoug N, Bembi B, Deegan P, Elstein D, Göker-Alpan Ö, Lukina E, Mengel E, Nakamura K, Pastores GM, Pérez-López J, Schwartz I, Serratrice C, Szer J, Zimran A, Di Rocco M, Panahloo Z, Kuter DJ, Hughes D.

Mol Genet Metab. 2017 Nov;122(3):122-129. doi: 10.1016/j.ymgme.2017.08.002. Epub 2017 Aug 4.

22.

Response to request by journal editorship from Blood Cells, Molecules and Diseases in reference to a "Dear Editor" letter to the Pastores et al. paper, 2016.

Pastores GM, Turkia HB, Gonzalez DE, Ida H, Tantawy AAG, Qin Y, Qiu Y, Dinh Q, Zimran A.

Blood Cells Mol Dis. 2017 Jun;65:71-72. doi: 10.1016/j.bcmd.2017.04.004. Epub 2017 Apr 13. No abstract available.

PMID:
28576608
23.

Plasma chitotriosidase activity versus CCL18 level for assessing type I Gaucher disease severity: protocol for a systematic review with meta-analysis of individual participant data.

Raskovalova T, Deegan PB, Yang R, Pavlova E, Stirnemann J, Labarère J, Zimran A, Mistry PK, Berger M.

Syst Rev. 2017 Apr 20;6(1):87. doi: 10.1186/s13643-017-0483-x.

24.

Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease.

Biegstraaten M, Cox TM, Belmatoug N, Berger MG, Collin-Histed T, Vom Dahl S, Di Rocco M, Fraga C, Giona F, Giraldo P, Hasanhodzic M, Hughes DA, Iversen PO, Kiewiet AI, Lukina E, Machaczka M, Marinakis T, Mengel E, Pastores GM, Plöckinger U, Rosenbaum H, Serratrice C, Symeonidis A, Szer J, Timmerman J, Tylki-Szymańska A, Weisz Hubshman M, Zafeiriou DI, Zimran A, Hollak CEM.

Blood Cells Mol Dis. 2018 Feb;68:203-208. doi: 10.1016/j.bcmd.2016.10.008. Epub 2016 Oct 24.

25.

Children with type 1 Gaucher disease: Changing profiles in the 21st century.

Elstein D, Altarescu G, Abrahamov A, Zimran A.

Blood Cells Mol Dis. 2018 Feb;68:93-96. doi: 10.1016/j.bcmd.2016.12.009. Epub 2016 Dec 19.

PMID:
28185830
26.

Are transient and shear wave elastography useful tools in Gaucher disease?

Webb M, Zimran A, Dinur T, Shibolet O, Levit S, Steinberg DM, Salomon O.

Blood Cells Mol Dis. 2018 Feb;68:143-147. doi: 10.1016/j.bcmd.2016.12.010. Epub 2016 Dec 23.

PMID:
28063644
27.

Classifying the additional morbidities of Gaucher disease.

Langeveld M, Elstein D, Szer J, Hollak CEM, Zimran A.

Blood Cells Mol Dis. 2018 Feb;68:209-210. doi: 10.1016/j.bcmd.2016.12.006. Epub 2016 Dec 19. No abstract available.

PMID:
28024892
28.

Growth and final height of children with Gaucher disease: A 15-year follow-up at an Israeli Gaucher center.

Mendelsohn E, Meir A, Abrahamov A, Elstein D, Zimran A, Levy-Khademi F.

Blood Cells Mol Dis. 2018 Feb;68:97-99. doi: 10.1016/j.bcmd.2016.11.014. Epub 2016 Dec 9.

PMID:
27993449
29.

Combined beta-glucosylceramide and ambroxol hydrochloride in patients with Gaucher related Parkinson disease: From clinical observations to drug development.

Ishay Y, Zimran A, Szer J, Dinur T, Ilan Y, Arkadir D.

Blood Cells Mol Dis. 2018 Feb;68:117-120. doi: 10.1016/j.bcmd.2016.10.028. Epub 2016 Nov 12. Review.

PMID:
27866808
30.

Trio approach reveals higher risk of PD in carriers of severe vs. mild GBA mutations.

Arkadir D, Dinur T, Mullin S, Mehta A, Baris HN, Alcalay RN, Zimran A.

Blood Cells Mol Dis. 2018 Feb;68:115-116. doi: 10.1016/j.bcmd.2016.11.007. Epub 2016 Nov 12.

PMID:
27864021
31.

UPR activation and CHOP mediated induction of GBA1 transcription in Gaucher disease.

Braunstein H, Maor G, Chicco G, Filocamo M, Zimran A, Horowitz M.

Blood Cells Mol Dis. 2018 Feb;68:21-29. doi: 10.1016/j.bcmd.2016.10.025. Epub 2016 Nov 3.

PMID:
27856178
32.

Bone mineral density and lean muscle mass characteristics in children with Gaucher disease treated with enzyme replacement therapy or untreated.

Dar L, Tiomkin M, Elstein D, Zimran A, Lebel E.

Blood Cells Mol Dis. 2018 Feb;68:135-138. doi: 10.1016/j.bcmd.2016.10.006. Epub 2016 Nov 9. No abstract available.

PMID:
27847274
33.

Liver involvement in Gaucher disease - Review and clinical approach.

Adar T, Ilan Y, Elstein D, Zimran A.

Blood Cells Mol Dis. 2018 Feb;68:66-73. doi: 10.1016/j.bcmd.2016.10.001. Epub 2016 Oct 19. Review.

PMID:
27842801
34.

Reported outcomes of 453 pregnancies in patients with Gaucher disease: An analysis from the Gaucher outcome survey.

Lau H, Belmatoug N, Deegan P, Goker-Alpan O, Schwartz IVD, Shankar SP, Panahloo Z, Zimran A.

Blood Cells Mol Dis. 2018 Feb;68:226-231. doi: 10.1016/j.bcmd.2016.10.003. Epub 2016 Oct 20.

35.

Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase.

Zimran A, Gonzalez-Rodriguez DE, Abrahamov A, Cooper PA, Varughese S, Giraldo P, Petakov M, Tan ES, Chertkoff R.

Blood Cells Mol Dis. 2018 Feb;68:163-172. doi: 10.1016/j.bcmd.2016.10.005. Epub 2016 Oct 20.

36.

Treatment-naïve Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4years in phase 3 trials.

Zimran A, Elstein D, Gonzalez DE, Lukina EA, Qin Y, Dinh Q, Turkia HB.

Blood Cells Mol Dis. 2018 Feb;68:153-159. doi: 10.1016/j.bcmd.2016.10.007. Epub 2016 Oct 21.

37.

Treatment patterns from 647 patients with Gaucher disease: An analysis from the Gaucher Outcome Survey.

Deegan P, Fernandez-Sasso D, Giraldo P, Lau H, Panahloo Z, Zimran A.

Blood Cells Mol Dis. 2018 Feb;68:218-225. doi: 10.1016/j.bcmd.2016.10.014. Epub 2016 Oct 20.

38.

Comparison of Bone Mineral Density by Dual-Energy X-Ray Absorptiometry and Bone Strength by Speed-of-Sound Ultrasonography in Adults With Gaucher Disease.

Baskin E, Dinur T, Lebel E, Tiomkin M, Elstein D, Zimran A.

J Clin Densitom. 2016 Oct;19(4):465-470. doi: 10.1016/j.jocd.2015.12.002. Epub 2016 Jan 15.

PMID:
26781431
39.

Home infusion of intravenous velaglucerase alfa: Experience from pooled clinical studies in 104 patients with type 1 Gaucher disease.

Elstein D, Burrow TA, Charrow J, Giraldo P, Mehta A, Pastores GM, Lee HM, Mellgard B, Zimran A.

Mol Genet Metab. 2017 Jan - Feb;120(1-2):111-115. doi: 10.1016/j.ymgme.2016.08.005. Epub 2016 Aug 23.

40.

Long-term efficacy and safety results of taliglucerase alfa through 5years in adult treatment-naïve patients with Gaucher disease.

Zimran A, Durán G, Giraldo P, Rosenbaum H, Giona F, Petakov M, Terreros Muñoz E, Solorio-Meza SE, Cooper PA, Varughese S, Alon S, Chertkoff R.

Blood Cells Mol Dis. 2019 Sep;78:14-21. doi: 10.1016/j.bcmd.2016.07.002. Epub 2016 Jul 18.

41.

New Directions in Gaucher Disease.

Horowitz M, Elstein D, Zimran A, Goker-Alpan O.

Hum Mutat. 2016 Nov;37(11):1121-1136. doi: 10.1002/humu.23056. Epub 2016 Aug 21. Review.

PMID:
27449603
42.

Anthropometric adjustments are helpful in the interpretation of BMD and BMC Z-scores of pediatric patients with Prader-Willi syndrome.

Hangartner TN, Short DF, Eldar-Geva T, Hirsch HJ, Tiomkin M, Zimran A, Gross-Tsur V.

Osteoporos Int. 2016 Dec;27(12):3457-3464. Epub 2016 Jul 4.

PMID:
27377921
43.

Development of anti-velaglucerase alfa antibodies in clinical trial-treated patients with Gaucher disease.

Pastores GM, Turkia HB, Gonzalez DE, Ida H, Tantawy AA, Qin Y, Qiu Y, Dinh Q, Zimran A.

Blood Cells Mol Dis. 2016 Jul;59:37-43. doi: 10.1016/j.bcmd.2016.03.004. Epub 2016 Mar 5.

44.

Long-term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment-naïve patients with Gaucher disease.

Zimran A, Durán G, Mehta A, Giraldo P, Rosenbaum H, Giona F, Amato DJ, Petakov M, Muñoz ET, Solorio-Meza SE, Cooper PA, Varughese S, Chertkoff R, Brill-Almon E.

Am J Hematol. 2016 Jul;91(7):656-60. doi: 10.1002/ajh.24369. Epub 2016 Apr 24.

45.

Clinical course and prognosis in patients with Gaucher disease and parkinsonism.

Lopez G, Kim J, Wiggs E, Cintron D, Groden C, Tayebi N, Mistry PK, Pastores GM, Zimran A, Goker-Alpan O, Sidransky E.

Neurol Genet. 2016 Mar 4;2(2):e57. doi: 10.1212/NXG.0000000000000057. eCollection 2016 Apr.

46.

Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase.

Pastores GM, Shankar SP, Petakov M, Giraldo P, Rosenbaum H, Amato DJ, Szer J, Chertkoff R, Brill-Almon E, Zimran A.

Am J Hematol. 2016 Jul;91(7):661-5. doi: 10.1002/ajh.24399. Epub 2016 May 18.

47.

13,845 home therapy infusions with velaglucerase alfa exemplify safety of velaglucerase alfa and increased compliance to every-other-week intravenous enzyme replacement therapy for Gaucher disease.

Elstein D, Abrahamov A, Oz A, Arbel N, Baris H, Zimran A.

Blood Cells Mol Dis. 2015 Dec;55(4):415-8. doi: 10.1016/j.bcmd.2015.09.002. Epub 2015 Sep 21. Review.

PMID:
26460268
48.

Proof-of-principle rapid noninvasive prenatal diagnosis of autosomal recessive founder mutations.

Zeevi DA, Altarescu G, Weinberg-Shukron A, Zahdeh F, Dinur T, Chicco G, Herskovitz Y, Renbaum P, Elstein D, Levy-Lahad E, Rolfs A, Zimran A.

J Clin Invest. 2015 Oct 1;125(10):3757-65. doi: 10.1172/JCI79322. Epub 2015 Aug 31.

49.

Color Discrimination in Patients with Gaucher Disease and Parkinson Disease.

Simon-Tov S, Dinur T, Giladi N, Bar-Shira A, Zelis M, Zimran A, Elstein D.

J Parkinsons Dis. 2015;5(3):525-31. doi: 10.3233/JPD-150585.

PMID:
26406132
50.

Gaucher disease types 1 and 3: Phenotypic characterization of large populations from the ICGG Gaucher Registry.

Grabowski GA, Zimran A, Ida H.

Am J Hematol. 2015 Jul;90 Suppl 1:S12-8. doi: 10.1002/ajh.24063. Review.

Supplemental Content

Loading ...
Support Center